135 related articles for article (PubMed ID: 38453738)
1. The enigma of glutamine synthetase and b-catenin expression in hepatocellular adenoma in familial adenomatous polyposis coli.
Gouw ASH; Sempoux C; Bioulac-Sage P
Virchows Arch; 2024 Apr; 484(4):553-554. PubMed ID: 38453738
[No Abstract] [Full Text] [Related]
2. Glutamine synthetase interpretation in hepatocellular adenoma.
Balabaud C; Bioulac-Sage P
Virchows Arch; 2014 Oct; 465(4):495-6. PubMed ID: 25216583
[No Abstract] [Full Text] [Related]
3. β-catenin activated hepatocellular adenoma.
Chu HH; Moon WS
Clin Mol Hepatol; 2013 Jun; 19(2):185-9. PubMed ID: 23837144
[No Abstract] [Full Text] [Related]
4. A Limited Immunohistochemical Panel Can Subtype Hepatocellular Adenomas for Routine Practice.
Larson BK; Guindi M
Am J Clin Pathol; 2017 Jun; 147(6):557-570. PubMed ID: 28472207
[TBL] [Abstract][Full Text] [Related]
5. Hepatocellular carcinoma arising in a pigmented telangiectatic adenoma with nuclear β-catenin and glutamine synthetase positivity: case report and review of the literature.
Hechtman JF; Raoufi M; Fiel MI; Taouli B; Facciuto M; Schiano TD; Blouin AG; Thung SN
Am J Surg Pathol; 2011 Jun; 35(6):927-32. PubMed ID: 21572265
[TBL] [Abstract][Full Text] [Related]
6. Integrated genotype-phenotype analysis of familial adenomatous polyposis-associated hepatocellular adenomas.
Tóth M; Kirchner M; Longerich T; Stenzinger A; Schirmacher P
Virchows Arch; 2024 Apr; 484(4):587-595. PubMed ID: 37872280
[TBL] [Abstract][Full Text] [Related]
7. Diffuse glutamine synthetase overexpression restricted to areas of peliosis in a β-catenin-activated hepatocellular adenoma: a potential pitfall in glutamine synthetase interpretation.
Berry RS; Gullapalli RR; Wu J; Morris K; Hanson JA
Virchows Arch; 2014 Aug; 465(2):241-5. PubMed ID: 24997695
[TBL] [Abstract][Full Text] [Related]
8. Correlation of exon 3 β-catenin mutations with glutamine synthetase staining patterns in hepatocellular adenoma and hepatocellular carcinoma.
Hale G; Liu X; Hu J; Xu Z; Che L; Solomon D; Tsokos C; Shafizadeh N; Chen X; Gill R; Kakar S
Mod Pathol; 2016 Nov; 29(11):1370-1380. PubMed ID: 27469330
[TBL] [Abstract][Full Text] [Related]
9. Hepatocellular carcinoma arising in adenoma: similar immunohistochemical and cytogenetic features in adenoma and hepatocellular carcinoma portions of the tumor.
Kakar S; Grenert JP; Paradis V; Pote N; Jakate S; Ferrell LD
Mod Pathol; 2014 Nov; 27(11):1499-1509. PubMed ID: 24743216
[TBL] [Abstract][Full Text] [Related]
10. Multifocal hepatic neoplasia in 3 children with APC gene mutation.
Gupta A; Sheridan RM; Towbin A; Geller JI; Tiao G; Bove KE
Am J Surg Pathol; 2013 Jul; 37(7):1058-66. PubMed ID: 23715166
[TBL] [Abstract][Full Text] [Related]
11. Focal β-catenin mutation identified on formalin-fixed and paraffin-embedded inflammatory hepatocellular adenomas.
Saldarriaga J; Bisig B; Couchy G; Castain C; Zucman-Rossi J; Balabaud C; Sempoux C; Bioulac-Sage P
Histopathology; 2017 Dec; 71(6):989-993. PubMed ID: 28618047
[TBL] [Abstract][Full Text] [Related]
12. Hepatocellular adenomas in a large community population, 2000 to 2010: reclassification per current World Health Organization classification and results of long-term follow-up.
Shafizadeh N; Genrich G; Ferrell L; Kakar S
Hum Pathol; 2014 May; 45(5):976-83. PubMed ID: 24746201
[TBL] [Abstract][Full Text] [Related]
13. Authors' response.
Berry RS; Hanson JA
Virchows Arch; 2014 Oct; 465(4):497-8. PubMed ID: 25148867
[No Abstract] [Full Text] [Related]
14. Utility of an immunohistochemical panel consisting of glypican-3, heat-shock protein-70, and glutamine synthetase in the distinction of low-grade hepatocellular carcinoma from hepatocellular adenoma.
Lagana SM; Salomao M; Bao F; Moreira RK; Lefkowitch JH; Remotti HE
Appl Immunohistochem Mol Morphol; 2013 Mar; 21(2):170-6. PubMed ID: 22914605
[TBL] [Abstract][Full Text] [Related]
15. Diagnostic utility and limitations of glutamine synthetase and serum amyloid-associated protein immunohistochemistry in the distinction of focal nodular hyperplasia and inflammatory hepatocellular adenoma.
Joseph NM; Ferrell LD; Jain D; Torbenson MS; Wu TT; Yeh MM; Kakar S
Mod Pathol; 2014 Jan; 27(1):62-72. PubMed ID: 23807780
[TBL] [Abstract][Full Text] [Related]
16. Validation of a liver adenoma classification system in a tertiary referral centre: implications for clinical practice.
van Aalten SM; Verheij J; Terkivatan T; Dwarkasing RS; de Man RA; Ijzermans JN
J Hepatol; 2011 Jul; 55(1):120-5. PubMed ID: 21145863
[TBL] [Abstract][Full Text] [Related]
17. Hepatocellular adenoma subtype classification using molecular markers and immunohistochemistry.
Bioulac-Sage P; Rebouissou S; Thomas C; Blanc JF; Saric J; Sa Cunha A; Rullier A; Cubel G; Couchy G; Imbeaud S; Balabaud C; Zucman-Rossi J
Hepatology; 2007 Sep; 46(3):740-8. PubMed ID: 17663417
[TBL] [Abstract][Full Text] [Related]
18. Hepatocellular adenoma classification: a comparative evaluation of immunohistochemistry and targeted mutational analysis.
Margolskee E; Bao F; de Gonzalez AK; Moreira RK; Lagana S; Sireci AN; Sepulveda AR; Remotti H; Lefkowitch JH; Salomao M
Diagn Pathol; 2016 Mar; 11():27. PubMed ID: 26961851
[TBL] [Abstract][Full Text] [Related]
19. Glutamine synthetase mediates sorafenib sensitivity in β-catenin-active hepatocellular carcinoma cells.
Sohn BH; Park IY; Shin JH; Yim SY; Lee JS
Exp Mol Med; 2018 Jan; 50(1):e421. PubMed ID: 29303508
[TBL] [Abstract][Full Text] [Related]
20. Nuclear beta-catenin staining and absence of steatosis are indicators of hepatocellular adenomas with an increased risk of malignancy.
Van der Borght S; Libbrecht L; Katoonizadeh A; Aerts R; Nevens F; Verslype C; Roskams TA
Histopathology; 2007 Dec; 51(6):855-6. PubMed ID: 17903198
[No Abstract] [Full Text] [Related]
[Next] [New Search]
